Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
GLOBALFOUNDRIES heads into its November 3 earnings date with options traders turning noticeably more bullish while short sellers quietly reduce their exposure, a combination that sets up an interesting tension with a Street consensus that remains firmly sidelined.
The clearest shift this week is in options positioning. Call demand has overtaken puts to a degree unusual for this stock. The put/call ratio has dropped to 0.90, more than 1.5 standard deviations below its 20-day average of 1.01, placing it among the more call-heavy readings of the past year. As recently as late August and early September, the ratio was running above 1.30. The move from defensive to offensive has been steady and sustained across six weeks, not a single session spike.
Short positioning reinforces that picture, though the story is modest. Short interest in GFS is only 1.4% of free float, too low to be a primary driver of anything. What is notable is the direction: shares short have built up about 46% from their late-August trough, rising from roughly 5.2 million to 7.6 million through mid-September before easing back 1.3% this week. The borrow market is entirely unconstrained. Availability is running at nearly 1,200%, meaning shares to lend outnumber shares already borrowed by a factor of roughly 12. Cost to borrow is 0.39%, down 18% on the week. There is no squeeze pressure here, and no meaningful crowding.
Analyst coverage tells a more cautious story than the options market does. The consensus is a hold, with eight analysts at that level against three outperforms. The mean price target is $74.68, implying roughly 55% upside from the current $48.07, though that gap partly reflects the spread in targets rather than unified conviction. The most recent action, Stifel initiating at Buy with a $60 target in early September, added one constructive voice. Before that, both TD Cowen and UBS trimmed targets in August following last quarter's print, with Cowen cutting from $85 to $75 and UBS from $61 to $55. The bulls point to Comm Infra and Data Center growing at high-30% year-on-year, silicon photonics capacity booked through 2027, and Q1 gross margin beating guidance by 200 basis points. Bears focus on a revenue CAGR of negative 6% over the 2022 to 2025 period, lost AMD and Marvell sockets, and the risk that mature-node overcapacity hits pricing. On valuation, the stock trades at 19.5 times earnings and 8.7 times EV/EBITDA, with EV/EBITDA compressing slightly over the past 30 days even as the price has risen 6%.
The ownership structure is worth flagging. Abu Dhabi's Mubadala Investment Company controls 72.8% of shares outstanding, a stake that declined from 77.1% at its last 13G/A filing in August. Fidelity, the second-largest disclosed holder, lifted its stake from 11.5% to 12.7% in the same filing window. Both filings are passive Schedule 13G disclosures. There is no activist holder on the register. Insider activity over the past 90 days has been almost entirely planned sales through 10b5-1 programmes, mostly the Chief Legal Officer selling 335 shares per week on a pre-set schedule. These are routine, low-conviction disposals, not directional signals.
Wikipedia attention for GFS jumped to a z-score of 2.27 versus its own 90-day history in late September, the highest retail attention reading available. It is a measure of interest, not a revenue indicator, and ORTEX has no measured leading dataset for this company's financials.
The prior two earnings prints produced a day-one drop of roughly 3% and 1% respectively, both recovering to small gains by day five. With results due November 3, the next four weeks resolve whether the options market's recent shift toward calls is vindicated by a print that improves on the Q3 guide of $1.76 billion, or whether the bears' long-running concern about top-line momentum reasserts itself.
See the live data behind this article on ORTEX.
Open GFS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
